Latest News

Ardelyx’s first-in-class NHE3 blocker Tenapanor boasts positive phase III data

Ardelyx’s first-in-class NHE3 blocker Tenapanor boasts positive phase III data

Eli Lilly Scores Phase III Migraine Success with Galcanezumab

Eli Lilly Scores Phase III Migraine Success with Galcanezumab

Studying unstable chromosomes can help predict cancer relapse, says Cancer Research UK

Studying unstable chromosomes can help predict cancer relapse, says Cancer Research UK

Valeant Pharmaceuticals lists price of plaque psoriasis drug at $3,500 per month

Valeant Pharmaceuticals International has decided to set the price of its biologic psoriasis treatment, known as Siliq (brodalumab) injection, at $3,500 per...

Valeant Pharmaceuticals lists price of plaque psoriasis drug at $3,500 per month

US FDA declines approval of Eli Lilly and Incyte’s baricitinib drug to treat RA

Eli Lilly and partner Incyte have announced that the US Food and Drug Administration (FDA) has declined to approve a new drug, baricitinib, to treat moderate-to-severe rheumatoid arthritis...

US FDA declines approval of Eli Lilly and Incyte’s baricitinib drug to treat RA

Alk’s HDM tablet Acarizax secures approval for expansion in 12 European countries

Alk’s HDM tablet Acarizax secures approval for expansion in 12 European countries

Genentech's Tecentriq receives FDA-accelerated approval for advanced bladder cancer treatment

Roche Group member Genentech has received accelerated approval from the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) to treat patients with locally advanced or...

Genentech's Tecentriq receives FDA-accelerated approval for advanced bladder cancer treatment

US FDA approves Neurocrine’s Ingrezza capsules to treat tardive dyskinesia

US FDA approves Neurocrine’s Ingrezza capsules to treat tardive dyskinesia

SMC approves anti-HIV drug PrEP

The Scottish Medicines Consortium (SMC) has approved the treatment known as Pre Exposure Prophylaxis (PrEP) that reduces the chances of being infected with...

SMC approves anti-HIV drug PrEP

US scientists identify ‘weak spot’ in Zika virus proteins

US scientists identify ‘weak spot’ in Zika virus proteins

NICE’s draft guidance ignores recommendation of Opdivo to treat cancer, Bristol-Myers Squibb says

US-based Bristol-Myers Squibb has confirmed that the National Institute for Health and Care Excellence (NICE) has issued draft guidance that ignores recommendation of investigational...

NICE’s draft guidance ignores recommendation of Opdivo to treat cancer, Bristol-Myers Squibb says

Zambon launches Xadago in Portugal to treat Parkinson’s disease

Zambon launches Xadago in Portugal to treat Parkinson’s disease

Supernus’ sNDAs receive final FDA approval for Trokendi XR for migraine prophylaxis

Supernus Pharmaceuticals has received the final approval from the US Food and Drug Administration (FDA) for its supplemental new drug applications (sNDAs) requesting a label expansion for Trokendi...

Supernus’ sNDAs receive final FDA approval for Trokendi XR for migraine prophylaxis

CN Bio licences Hepatitis B drug discovery programme from Bristol-Myers Squibb

CN Bio licences Hepatitis B drug discovery programme from Bristol-Myers Squibb

Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia

Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia

US FDA approves Teva’s Austedo tablets to treat chorea associated with HD

Teva Pharmaceutical’s Austedo (deutetrabenazine) tablets have been approved by the US Food and Drug Administration (FDA) to treat chorea associated with Huntington’s disease (HD)....

US FDA approves Teva’s Austedo tablets to treat chorea associated with HD

Astellas Pharma to acquire Belgium’s Ogeda for €800m

Japanese company Astellas Pharma has signed an agreement to acquire Belgium-based drug discovery company Ogeda in a deal valued at €800m....

Astellas Pharma to acquire Belgium’s Ogeda for €800m

Sucampo Pharmaceuticals acquires rare disease company Vtesse for $200m

Sucampo Pharmaceuticals acquires rare disease company Vtesse for $200m

Mundipharma’s Mundesine receives approval from Japan’s MHLW to treat PTCL

Mundipharma has secured regulatory approval of Mundesine (Forodesine hydrochloride) from Japan’s Ministry of Health, Labour and Welfare (MHLW) to treat relapsed / refractory Peripheral...

Mundipharma’s Mundesine receives approval from Japan’s MHLW to treat PTCL

NHS England announces new Five Year Forward View

NHS England has announced the new Five Year Forward View ‘Next Steps’ Plan to further improve cancer survival by an extra 5,000...

NHS England announces new Five Year Forward View

US researchers develop new approach to improve HIV vaccine effectiveness

US researchers develop new approach to improve HIV vaccine effectiveness
cachename:Newscachekey:rd-137342983_-144940029_rd-1665407042_1857678299_rd-488908060_1460672566_ap1460672566_1857678299_651428199